natgillin/translations-raw huggingface dataset:
LPV/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
LPV/RTV skupaj z dizoproksiltenofovirijevim fumaratom/emtricitabinom (fiksni odmerek 300 mg/200 mg tablete enkrat na dan).
Atazanavir Mylan 150 mg capsules are greenish-blue and blue opaque hard shell gelatin capsules filled with white to pale yellow powder and approximately 19.3 mm in length.
Zdravilo Atazanavir Mylan 150 mg trde kapsule so zelenkasto-modre in modre neprozorne trde želatinaste kapsule, napolnjene z belim do bledo rumenim prahom in dolge približno 19,3 mm. Kapsule imajo na pokrovčku in telesu kapsule s črnim črnilom vzdolžno odtisnjeno oznako 'MYLAN' preko 'AR150'.
Atazanavir is expected to increase plasma levels of lurasidone due to CYP3A4 inhibition.
Atazanavir lahko z zaviranjem CYP3A4 zviša vrednosti lurasidona v plazmi.
Vascular disorders:
dispepsija (prebavne motnje);
Therefore, such co-administration is not recommended.
Uporabi takih kontraceptivov se je tako treba izogibati.
Atazanavir with ritonavir has not been studied in patients with hepatic impairment.
Pri bolnikih z okvaro jeter uporabe atazanavirja z ritonavirjem niso proučevali.
(n=36)
Po porodua (n=36)
Posology
Mehanizem
(range: 100 to 1157 cells/ mm 3) and mean baseline plasma HIV 1 RNA was 4.09 log10 copies/ml (range: 3.28 to 5.00 log10 copies/ml).
3) in povprečna začetna plazemska vrednost HIV 1 RNA 4,09 log10 kopij/ml (območje: 3,28 do 5,00 log10 kopij/ml).
Grazoprevir concentrations were greatly increased when co-administered with atazanavir/ritonavir.
Izjema sta bila le zlatenica in zvišanje vrednosti celotnega bilirubina, ki sta bila pri uporabi atazanavirja skupaj z ritonavirjem pogostejša.
Co-administration with atazanavir may result in increased concentrations of salmeterol and an
Pri sočasni uporabi atazanavirja se koncentracije salmeterola lahko povečajo in s tem se poveča tudi pojavnost neželenih učinkov salmeterola.
Sildenafil
Mylan
(atazanavir 400 mg once daily with ritonavir 200 mg once daily)
efavirenz 600 mg enkrat na dan (atazanavir 400 mg enkrat na dan z ritonavirjem 200 mg enkrat na dan)
BLISTER CARTON FOR 300 MG HARD CAPSULES
PRETISNI OMOTI ZA 300 MG TRDE KAPSULE
In HIV-infected patients with atazanavir/ritonavir at an increased dose of 400/100 mg once daily
Pri z virusom HIV okuženih bolnikih, ki so se zdravili z atazanavirjem/ritonavirjem v zvišanem odmerku 400 mg/100 mg enkrat na dan famotidin 20 mg dvakrat na dan atazanavir AUC ↑18 %
common: jaundice; uncommon: hepatitis, cholelithiasis a, cholestasis a;
pogosti: zlatenica; občasni: vnetje jeter, holelitiaza a, holestaza a; redki: povečanje jeter in vranice, vnetje žolčnika a
De novo substitutions in treatment naive patients failing therapy with atazanavir +
Preglednica 3: Pojav novih substitucij pri predhodno še nezdravljenih bolnikih po neuspešnem zdravljenju z atazanavirjem + ritonavirjem (Študija 138, 96 tednov)
In female mice, atazanavir exposure at a dose that produced single-cell necrosis was 12 times the exposure in humans given 400 mg once daily.
Pri mišjih samicah je bila izpostavljenost atazanavirju ob odmerku, ki je povzročil nekrozo posameznih jetrnih celic, 12-krat tolikšna kot je izpostavljenost pri človeku ob uporabi 400 mg enkrat na dan. Serumski holesterol in glukoza sta se pri podganah zvišala minimalno do blago, pri miših in psih pa se nista zvišala.
Co-administration of efavirenz and atazanavir is not recommended (see section 4.4)
Sočasna uporaba efavirenza in atazanavirja ni priporočljiva (glejte poglavje 4.4).
Atazanavir Cmin ↓20% (↓31% ↓8%) In Healthy volunteers with atazanavir/ritonavir at an increased dose of 400/100 mg once daily
Pri zdravih prostovoljcih, ki so prejemali atazanavir/ritonavir v večjem odmerku, to je 400 mg/100 mg enkrat na dan famotidin 40 mg dvakrat na dan atazanavir AUC ↔3 %
BLISTER CARTON FOR 150 MG HARD CAPSULES
PRETISNI OMOTI ZA 150 MG TRDE KAPSULE
Co-administration of atazanavir and elbasvir/grazoprevir is contraindicated because of a significant increase in grazoprevir plasma concentrations and an associated
Pri sočasni uporabi atazanavirja/ritonavirja so se koncentracije grazoprevirja močno povečale.
This summary was last updated in 11-2014.
Povzetek je bil nazadnje posodobljen 11-2014.
The recommended dose is 200 mg taken twice a day (around 12 hours apart).
Priporočeni odmerek je 200 mg dvakrat na dan (s presledkom približno 12 ur).
The European Commission granted a marketing authorisation valid throughout the European Union for Vargatef on 21 November 2014.
Evropska komisija je dovoljenje za promet z zdravilom Vargatef, veljavno po vsej Evropski uniji, izdala 21. novembra 2014.
If severe side effects persist, treatment should be permanently discontinued.
Če hudi neželeni učinki vztrajajo, je treba zdravljenje trajno prekiniti.
The full EPAR and risk management plan summary for Vargatef can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Vargatef sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Vargatef.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vargatef.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom cycle, Vargatef is given on days 2 to 21 with docetaxel being given on day 1.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom zdravljenja, se zdravilo Vargatef daje od 2. do 21. dneva, docetaksel pa 1. dan.
Other information about Vargatef
Druge informacije o zdravilu Vargatef
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Vargatef's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Vargatef večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
In addition, the company that markets Vargatef will conduct studies to find ways to identify those patients who are most likely to benefit from treatment with the medicine.
Poleg tega bo družba, ki trži zdravilo Vargatef, izvedla študije, s katerimi bo ugotovila načine za prepoznavanje tistih bolnikov, za katere je najverjetneje, da jim bo zdravljenje s tem zdravilom koristilo.
A risk management plan has been developed to ensure that Vargatef is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Vargatef je bil pripravljen načrt obvladovanja tveganj.
These enzymes can be found in certain receptors (such as VEGF, FGF and PDGF receptors) on the surface of cancer cells and on the cells of the surrounding tissue (e.g. blood vessel), where they activate several processes including cell division and the growth of new blood vessels.
Te encime lahko najdemo v različnih receptorjih (kot so receptorji VEGF, FGF in PDGF) na površini rakavih celic in na celicah v okolnem tkivu (npr. krvni žili), kjer aktivirajo številne procese, vključno z delitvijo celic in rastjo novih krvnih žil.
Vargatef is available as capsules (100 and 150 mg) to be taken by mouth, preferably with food.
Zdravilo Vargatef je na voljo v obliki kapsul (100 mg in 150 mg), ki se jemljejo peroralno, najbolje s hrano.
By blocking these enzymes, nintedanib helps to reduce the growth and spread of the cancer and to cut off the blood supply that keeps cancer cells growing.
Z zaviranjem teh encimov nintedanib pomaga zmanjšati rast in širjenje raka ter prekiniti oskrbo s krvjo, ki omogoča rast rakavih celic.
Vargatef is used to treat a type of non-small cell lung cancer called ‘adenocarcinoma', when the cancer is locally advanced, metastatic (when cancer cells have spread from the original site to other parts of the body) or locally recurrent (when the cancer has come back in the same area).
Zdravilo Vargatef se uporablja za zdravljenje vrste nedrobnoceličnega pljučnega raka, imenovanega „adenokarcinom“, ko je rak lokalno napredoval, metastatski (ko se rakave celice razširijo s prvotnega mesta na druge dele telesa) ali lokalno rekurenten (ko se rak ponovi na istem mestu).
Vargatef must not be used in patients who are hypersensitive (allergic) to nintedanib, peanut or soya, or any of the other ingredients.
Zdravilo Vargatef se ne sme uporabljati pri bolnikih, ki so preobčutljivi (alergični) na nintedanib, arašide, sojo ali katero koli drugo sestavino zdravila.
Because Vargatef must not be given on the same day as docetaxel and because docetaxel is given on day 1 of a 21-day treatment
Ker se zdravilo Vargatef ne sme uporabiti isti dan kot docetaksel in ker se docetaksel daje 1. dan 21─dnevnega
The most common side effects with Vargatef (which may affect more than 1 in 10 people) include diarrhoea, vomiting and increased blood levels of certain liver enzymes (a sign of possible liver problems).
Najpogostejši neželeni učinki zdravila Vargatef (ki se lahko pojavijo pri več kot 1 od 10 bolnikov) vključujejo drisko, bruhanje in povišane ravni nekaterih jetrnih encimov v krvi (znak morebitnih težav z jetri).
What measures are being taken to ensure the safe and effective use of Vargatef?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila
What is Vargatef and what is it used for?
Kaj je zdravilo Vargatef in za kaj se uporablja?
If severe side effects develop, the doctor may decide to interrupt treatment with Vargatef and resume it at a lower dose.
Če se razvijejo hudi neželeni učinki, se lahko zdravnik odloči za prekinitev zdravljenja z zdravilom Vargatef in ponovno zdravljenje z manjšim odmerkom.
What are the risks associated with Vargatef?
Kakšna tveganja so povezana z zdravilom Vargatef?
The medicine is used in combination with a chemotherapy medicine called docetaxel in patients who have already received previous treatment with chemotherapy.
To zdravilo se uporablja v kombinaciji s kemoterapevtikom, imenovanim docetaksel, pri bolnikih, ki so se že predhodno zdravili s kemoterapijo.
The active substance in Vargatef, nintedanib, blocks the activity of some enzymes known as tyrosine kinases.
Zdravilna učinkovina v zdravilu Vargatef, nintedanib, zavira dejavnost nekaterih encimov, imenovanih tirozin-kinaze.
Vargatef can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.
Izdaja zdravila Vargatef je le na recept, zdravljenje z njim pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
Why is Vargatef approved?
Zakaj je bilo zdravilo Vargatef odobreno?
What benefits of Vargatef have been shown in studies?
Kakšne koristi je zdravilo Vargatef izkazalo v študijah?
In a main study involving 1,314 patients with advanced or recurrent non-small cell lung cancer that did not respond to a previous treatment, Vargatef taken in combination with docetaxel was shown to be more effective than docetaxel alone at delaying progression of the cancer.
V glavni študiji, ki je vključila 1 314 bolnikov z napredovalim ali rekurentnim nedrobnoceličnim pljučnim rakom, ki se niso odzvali na predhodno zdravljenje, so pokazali, da je bilo zdravilo Vargatef v kombinaciji z docetakselom učinkovitejše pri upočasnitvi napredovanja raka kot docetaksel v monoterapiji.
For more information about treatment with Vargatef, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Vargatef preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vargatef, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Vargatef in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Vargatef is a cancer medicine used to treat adults with a type of lung cancer known as non-small cell lung cancer.
Vargatef je zdravilo za zdravljenje raka, ki se uporablja za zdravljenje odraslih bolnikov z vrsto pljučnega raka, ki se imenuje nedrobnocelični pljučni rak.
Treatment with Vargatef may continue after stopping docetaxel, for as long as the disease improves or remains stable and the side effects are tolerable.
Po prekinitvi uporabe docetaksela se lahko zdravljenje z zdravilom Vargatef nadaljuje, dokler se bolezen izboljšuje ali ostane stabilna in bolnik prenaša neželene učinke.
The CHMP noted that Vargatef was effective at slowing down disease progression and prolonging life in the subgroup of patients with non-small cell lung cancer of the adenocarcinoma type.
Odbor CHMP je ugotovil, da je bilo zdravilo Vargatef učinkovito pri upočasnitvi napredovanja bolezni in podaljšanju življenja pri podskupini bolnikov z nedrobnoceličnim pljučnim rakom vrste adenokarcinoma.
It is not intended to provide practical advice on how to use Vargatef.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For the full list of all side effects and restrictions with Vargatef, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Vargatef glejte navodilo za uporabo.
In addition, Vargatef led to an improvement in overall survival (how long patients lived) in the subgroup of patients with non-small cell lung cancer of the adenocarcinoma type: overall survival was 12.6 months in patients treated with Vargatef plus docetaxel, compared with 10.3 months in patients treated with docetaxel alone.
Poleg tega je zdravilo Vargatef izboljšalo splošno preživetje (kako dolgo so živeli) podskupine bolnikov z nedrobnoceličnim pljučnim rakom tipa adenokarcinoma: splošno preživetje pri bolnikih, zdravljenih z zdravilom Vargatef in docetakselom, je bilo 12,6 meseca, pri bolnikih, zdravljenih s samostojnim docetakselom, pa 10,3 meseca.
For practical information about using Vargatef, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Vargatef naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Regarding its safety, although more side effects were reported in patients treated with Vargatef plus docetaxel than in those treated with docetaxel alone, the side effects were considered manageable with dose reductions, supportive treatments and treatment interruptions.
Čeprav so glede varnosti pri bolnikih, zdravljenih z zdravilom Vargatef in docetakselom, poročali o več neželenih učinkih kot pri bolnikih, zdravljenih samo z docetakselom, je odbor menil, da so bili neželeni učinki obvladljivi z zmanjšanjem odmerka, podpornim zdravljenjem in prekinitvami zdravljenja.
Progression-free survival (the time patients lived without their disease getting worse) was 3.5 months in patients receiving Vargatef plus docetaxel, compared with 2.7 months in patients receiving docetaxel alone.
Preživetje brez napredovanja (čas, ko se bolnikova bolezen ni slabšala) je bilo pri bolnikih, ki so prejemali zdravilo Vargatef in docetaksel, 3,5 meseca, pri bolnikih, ki so prejemali docetaksel v monoterapiji, pa 2,7 meseca.
Vargatef contains the active substance nintedanib.
Zdravilo Vargatef vsebuje zdravilno učinkovino nintedanib.
How does Vargatef work?
Kako zdravilo Vargatef deluje?
EPAR summary for the public
Povzetek EPAR za javnost nintedanib
How is Vargatef used?
Kako se zdravilo Vergatef uporablja?
This summary was last updated in July 2014.
Povzetek je bil nazadnje posodobljen julija 2014.
The period of protection is 8 weeks.
Zaščita traja 8 tednov.
These reactions are very rare (affecting less than 1 bird in 10,000).
Te reakcije so zelo redke (prizadenejo manj kot 1 ptico od 10 000).
The Committee recommended that a further overdose study should be submitted.
Odbor je priporočil, da se predloži dodatna študija prevelikega odmerjanja.
The effectiveness of the vaccine was first studied in a number of laboratory studies in chickens.
Učinkovitost cepiva so najprej raziskali v več laboratorijskih študijah pri piščancih.
In the future if the animals are exposed to the virus the immune system will be able to respond more quickly.
Če so živali kasneje izpostavljene virusu, se lahko imunski sistem nanj hitreje odzove.
Hands and equipment should be washed and disinfected after vaccination to avoid spread of the virus.
Po cepljenju je treba umiti ter razkužiti roke in opremo, da se prepreči širjenje virusa.
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo“, kako naj se brani pred boleznijo.
This will help protect them against infectious bronchitis.
To pomaga zaščititi živali pred infekcioznim bronhitisom.
The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Razmerje med koristmi in tveganji je na voljo v modulu znanstvene razprave v tem povzetku.
The vaccine is to be made up into a suspension for use.
Cepivo je treba pred uporabo pripraviti v suspenzijo.
The vaccine is given to chickens from 1 day of age or older by spraying onto the chickens or by applying drops into the eyes or nostrils.
Cepivo se daje piščancem, starim 1 dan ali več, pri čemer ga je treba napršiti po piščancih ali v obliki kapljic nanesti v oči ali nosnice.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption.
Obdobje karence je čas, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje in meso, jajca ali mleko uporabi za prehrano ljudi.
Live avian infectious bronchitis virus strain D388
živ sev virusa aviarnega infekcioznega bronhitisa D388
If vaccinating by spray masks with eye protection should be worn when handling the product.
Pri nanašanju cepiva s pršilnikom je treba med rokovanjem z zdravilom nositi masko z zaščito za oči.
Nobilis IB Primo QX must not be given to birds which are laying eggs or within 4 weeks before the start of the laying period.
Zdravilo Nobilis IB Primo QX se ne sme dajati pticam, ki nesejo jajca, in v 4 tednih pred začetkom nesnega obdobja.
The laboratory studies showed that the vaccine had its full effect by three weeks and that protection lasted for eight weeks; protection was not affected by antibodies transmitted from the mother.
Laboratorijske študije so pokazale, da je imelo cepivo polni učinek po treh tednih in da je zaščita trajala osem tednov; protitelesa, ki so jih piščanci dobili od matere, niso vplivala na zaščito.
The avian infection bronchitis virus in Nobilis IB Primo QX has been attenuated (weakened) so that it does not cause disease.
Virus aviarnega infekcioznega bronhitisa v zdravilu Nobilis IB Primo QX je bil atenuiran (oslabljen), tako da ne povzroča bolezni.
Control groups of birds were unvaccinated to show the effectiveness of the challenge.
Ptičev v kontrolnih skupinah niso cepili, da bi dokazali učinkovitost provokacije.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobilis IB Primo QX exceed the risks for the approved indication and recommended that Nobilis IB Primo QX be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Nobilis IB Primo QX večje od z njim povezanih tveganj za odobreno indikacijo, in priporočil, da se zanj izda dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union, for Nobilis IB Primo QX on 4 September 2014.
Evropska komisija je dovoljenje za promet z zdravilom Nobilis IB Primo QX, veljavno po vsej Evropski uniji, izdala 4. septembra 2014.
The purpose of the studies was to establish how long it took for chickens to be fully protected, the length of time protection lasts against infectious bronchitis due to QX-like variants, as well as the influence of maternal antibodies (transmitted from the mother) on the effectiveness of the vaccine.
Namen študij je bil ugotoviti, kdaj piščanci postanejo popolnoma zaščiteni pred infekcioznim bronhitisom zaradi različic, podobnih QX, in koliko časa ta zaščita traja ter kako na učinkovitost cepiva vplivajo maternalna protitelesa (ki so jih piščanci dobili od matere).
In a second study 42 broiler chickens were spray vaccinated at 1 day old and challenged 3 weeks after vaccination with a QX strain of the virus.
V drugi študiji so 42 pitovnih piščancev, starih 1 dan, napršili s cepivom in jih 3 tedne po cepljenju izpostavili sevu virusa QX.
Two groups of 28 birds were challenged with the virus 3 weeks after vaccination, one group with a QX strain and the second group with another strain called M41.
Tri tedne po cepljenju so dve skupini po 28 ptičev izpostavili virusu, od tega eno skupino sevu QX, drugo pa drugemu sevu, imenovanemu M41.
When Nobilis IB Primo QX is given to chickens the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it.
Ko piščanci prejmejo cepivo Nobilis IB Primo QX, imunski sistem živali prepozna virus kot „tujek“ ter začne proti njemu tvoriti protitelesa.
In the first study broiler chickens (chickens bred for meat) were spray vaccinated with both Nobilis IB Primo QX and Nobilis IB Ma5, a vaccine against a Massachusetts strain of infectious bronchitis virus.
V prvi študiji so pitovne piščance (piščance, ki se redijo za meso) napršili s cepivoma Nobilis IB Primo QX in Nobilis IB Ma5, ki je cepivo proti massachusetskemu sevu virusa infekcioznega bronhitisa.
After vaccination a mild short lived reaction in the airways, including a nasal discharge, may occur for at least 10 days.
Vsaj še 10 dni po cepljenju se lahko pojavijo blage kratkotrajne reakcije v dihalih, vključno z izcedkom iz nosu.
Nobilis IB Primo QX is a veterinary vaccine that contains live attenuated (weakened) avian infectious bronchitis virus strain D388.
Nobilis IB Primo QX je cepivo za uporabo v veterinarski medicini, ki vsebuje živ atenuiran (oslabljen) sev virusa aviarnega infekcioznega bronhitisa D388.
The effectiveness of Nobilis IB Primo QX was investigated in two field studies.
Učinkovitost zdravila Nobilis IB Primo QX so raziskali v dveh terenskih študijah.
Nobilis IB Primo QX is used to protect chickens against viral infectious bronchitis caused by strains of infectious bronchitis virus known as QX-like variants, such as strain D388.
Zdravilo Nobilis IB Primo QX se uporablja za zaščito piščancev pred virusnim infekcioznim bronhitisom, ki ga povzročajo sevi virusa infekcioznega bronhitisa, ki jim pravimo različice, podobne QX, kot je na primer sev D388.
Nobilis IB Primo QX is a vaccine.
Nobilis IB Primo QX je cepivo.
Unvaccinated chicks were retained as controls to show the effectiveness of the challenge.
V kontrolnih skupinah so pustili necepljene piščance, da bi lahko dokazali učinkovitost provokacije.
The second field study showed 93% of the Nobilis IB Primo QX vaccinated birds and none of the unvaccinated birds to be protected from the challenge.
Druga terenska študija je pokazala, da je bilo pred provokacijo zaščitenih 93 % ptic, ki so bile cepljene s cepivom Nobilis IB Primo QX, medtem ko med necepljenimi pticami ni bila zaščitena nobena.
In the first field study 100% of the birds vaccinated with Nobilis IB Primo QX mixed with Nobilis IB Ma5 were protected from the QX strain and 90% were protected from M41, compared with none of the unvaccinated birds.
V prvi terenski študiji je bilo 100 % piščancev, ki so jih cepili z mešanico cepiva Nobilis IB Primo QX in Nobilis IB Ma5, zaščitenih pred sevom QX in 90 % pred sevom M41, medtem ko med necepljenimi piščanci ni bil zaščiten noben.
Nobilis IB Primo QX is available as a lyophilisate (freeze-dried powder) which may be supplied with a solvent.
Zdravilo Nobilis IB Primo QX je na voljo v obliki liofilizata (praška, posušenega v zamrznjenem stanju), ki mu je lahko priložen vehikel.